Field cancerisation and radiotherapy: a case of treatment complications
Authors: James Muir, Sarah K Morton and Selim Ozluer
Published online: 2 October 2023
In reply: We thank Fogarty and colleagues1 for their interest in our article.2 We presented a rare, life‐altering complication of field volumetric modulated arc therapy (VMAT) of the skin. Given the active promotion of VMAT to both clinicians and the public, and the paucity of long term efficacy and safety data, this case illustrates the need for multidisciplinary evidence‐based guidelines for its use.
Solar damage is a chronic disease requiring long term management. One author (JM) is a member of a multidisciplinary team including radiation oncology, dermatology, and plastic surgery.
The suggestion our patient was developing “hundreds” of lesions is inaccurate. In the ten years before VMAT, he had 20 keratinocyte carcinomas, including six squamous cell carcinomas, all treated in his dermatologist's rooms. He did have numerous actinic keratoses, which rarely progress to frank malignancy.
After VMAT, development of keratinocyte carcinomas accelerated aggressively, with larger, rapidly growing lesions occurring in greater numbers. Irradiation fibrosis required referral to a plastic surgeon for complex skin closures. Fogarty and colleagues’ claim that scarring from previous treatments significantly contributed to diffuse post‐VMAT fibrosis is unfounded. The ten years before VMAT saw one basosquamous carcinoma and one intra‐epidermal carcinoma on his upper limbs. The 3.5 years after VMAT, his skin produced ten invasive squamous cell carcinomas. Subsequently, opinion was sought from a medical oncologist. Cemiplimab was trialled but ceased due to lack of response and side effects.
Solar‐related skin disease is common. The majority of affected patients die “with” rather than “of” this condition.3 In a population where longevity is increasing and sun damage abounds, what degree of field cancerisation justifies the morbidity, expense, and side effects of VMAT?
A tenet of medicine is “first do no harm”. Currently, our view is there is no clear‐cut indication for VMAT in skin field cancerisation.2,4 Long term efficacy, safety data, and cost–benefit analysis are missing. Adequately powered controlled trials are the bedrock of evidence‐based medicine. As radiation side effects continue to develop for many years and recurrence rates for keratinocyte carcinoma are typically measured at least five to ten years after treatment,5 shorter trials would not meaningfully inform efficacy and safety; hence, our suggestion for prospective controlled trials over at least ten years.
Competing interests
References
- Fogarty GB, Paton EJ, Christie D. Field cancerisation and radiotherapy: a case of treatment complications [letter]. Med J Aust 2023; 219: 335.
- Morton SK, Ozluer S, Muir J. Field cancerisation and radiotherapy: a case of treatment complications. Med J Aust 2023; 219: 12‐14. https://www.mja.com.au/journal/2023/219/1/field‐cancerisation‐and‐radiotherapy‐case‐treatment‐complications
- Apalla Z, Lallas A, Sotiriou E, et al. Epidemiological trends in skin cancer. Dermatol Pract Concept 2017; 7: 1‐6.
- Daly T, Veness M, Poulsen M, et al. Wide‐field radiation therapy for skin cancerisation — have we forgotten what we learned? J Med Imaging Radiat Oncol 2023; 67: 128‐131.
- Caparrotti F, Troussier I, Ali A, Zilli T. Localized non‐melanoma skin cancer: risk factors of post‐surgical relapse and role of postoperative radiotherapy. Curr Treat Options Oncol 2020; 21: 97.
Challenges and Opportunities for Strong and Dynamic Foundations in the Australian Cancer Plan
Ashley M. Hopkins, Andrew Rowland, Natansh D. Modi, Ceara Rickard, Mark Haseloff, Norma B. Bulamu, Imogen Ramsey, Niranjan Bidargaddi, Ganessan Kichenadasse, Michael J. Sorich, Kalinda E. Griffiths, Aideen McInerney-Leo, David M. Roder, Raymond J. Chan
Opportunities and Challenges to Achieving the Australian Cancer Plan Goal of World Class Health Systems for Optimal Cancer Care
Carolyn Ee, Ria Joseph, Elise Button, Stacey George, Makala Castelli, David Currow, Prue Cormie, Olivia Farrer, Michael Jefford, Nicolas H. Hart, Chad Y. Han, Deidre D. Morgan, Michael P. Osborn, Candice Oster, Joel Rhee, Anna Ugalde, Eric Yeung, Catherine Paterson
Maximising Cancer Prevention and Early Detection in the Australian Cancer Plan: Where Are We Now and What Should Come Next?
Erin L. Symonds, Billie Bonevski, Richard Edwards, Nathan J. Harrison, Sana Ishaque, Nicole M. Rankin, Sibel Saya, Renee J. Smith, Carolyn Ee
An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres
Sarah Childs, David Ma, Anthony Rodrigues, Jennifer Massey, Rasha Cosman, Venessa Chin, Laila Girgis, James Lynam, Peter Lau, Barbara Withers, Anthony M. Joshua, Ben Tran, Jayesh Desai, Simon J. Harrison, John Moore, Jia Liu
Peritoneal Tuberculosis and Chronic Myeloid Leukaemia: A Case of Hickam's Dictum
Zayn Al-Timimi, Gem Chew, Martin Browne, Christiaan Mostert
From Ambition to Action: Closing Policy, Equity and Implementation Gaps in the Australian Cancer Plan's ‘Enhanced Consumer Experience’
Carla Thamm, Elise Button, Oluwaseyifunmi A. Agbejule, Reegan Knowles, Karen van Gorp, Mark B. Pinkham, Meinir Krishnasamy, Alexandra L. McCarthy, Raymond J. Chan